In a recent article, we discussed what makes Genfit’s (OTCPK:GNFTF) Elafibranor one of the most promising candidates in the NASH treatment development space. Given the unmet need (no approved therapies), Elafibranor’s mechanism of action and the potential it has shown in clinical stages, we see a strong chance of approval if the pivotal phase 3 study succeeds. In this article, we will briefly discuss the chances of Elafibranor’s success in clinical stages and Genfit’s valuation based on the potential of its lead product candidate. We will briefly also discuss the risks to the